DV
Dividend Vision

TRDA — Entrada Therapeutics Inc

Entrada Therapeutics Inc (TRDA)

Total return is -68.9% over the past 4.8 years, 149.2 points behind SPY at 80.3%. Its deepest 1-year drawdown was 64.8%.

TRDA is an equity fund focused on Entrada Therapeutics Inc, a single-stock holding established in October 2021. The fund provides direct exposure to this therapeutic company's equity performance, with no associated dividend distribution or yield profile. This structure appeals to investors seeking concentrated exposure to the company's growth potential rather than income generation, though the lack of available expense ratio and asset data limits full transparency on fund costs and scale.

TRDA key facts

Asset type
Stock
Asset class
Equity
Inception date
10/29/2021
Last close
$7.46
Market cap
$246,122,704
Average volume
238000.0
Beta
-0.264
Payout ratio
0.0
Forward P/E
3333.3333
EPS
$-4.00